Back to top
more

Fresenius Medical Care AG & Co. (FMS)

(Delayed Data from NYSE)

$24.42 USD

24.42
526,289

-0.52 (-2.09%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $24.42 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

CVS Health's Latest Alliances to Fortify Kidney-Care Business

by Zacks Equity Research

With a growing incidence of chronic kidney diseases and end-stage renal failure in the United States, CVS Health's (CVS) new partnerships seem to be strategic.

Zacks Equity Research

Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y

by Zacks Equity Research

Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong segmental performance and solid 2020 EPS outlook.

Zacks Equity Research

Should Value Investors Pick Fresenius Medical (FMS) Stock?

by Zacks Equity Research

Let's see if Fresenius Medical (FMS) stock is a good choice for value-oriented investors right now from multiple angles.

Zacks Equity Research

Fresenius (FMS) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Fresenius (FMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Is Fresenius (FMS) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Should Value Investors Buy Fresenius (FMS) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Fresenius Medical (FMS) Q3 Earnings & Revenues Top Estimates

by Zacks Equity Research

Fresenius Medical's (FMS) Q3 earnings benefit from strong segmental performance and solid 2019 EPS outlook.

Zacks Equity Research

Should Value Investors Buy Fresenius (FMS) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Here's Why You Should Retain Ecolab (ECL) Stock For Now

by Zacks Equity Research

Ecolab (ECL) continues to gain from robust product portfolio and strong international presence. However, forex remains a woe.

Zacks Equity Research

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.

Zacks Equity Research

Here's Why You Should Retain Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.

Zacks Equity Research

Is Fresenius (FMS) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Here's Why You Should Retain DaVita (DVA) Stock for Now

by Zacks Equity Research

DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, integration risks remain a concern.

Zacks Equity Research

Integer Holdings (ITGR) Boosts Product Line with New Buyout

by Zacks Equity Research

Integer Holdings' (ITGR) buyout is likely to add differentiated capability for complex braided and formed biomedical structures to the company's existing product portfolio.

Zacks Equity Research

Fresenius Medical Launches 4008A Dialysis Machine in China

by Zacks Equity Research

Fresenius Medical (FMS) aims to treat ESRD patients in remote locations of China.

Zacks Equity Research

Is Fresenius Medical (FMS) a Good Value Investor Pick Now?

by Zacks Equity Research

Let's see if Fresenius Medical (FMS) stock is a good choice for value-oriented investors right now from multiple angles.

Zacks Equity Research

Fresenius Medical (FMS) Q2 Earnings Miss Estimates, Down Y/Y

by Zacks Equity Research

Strong segmental performance and solid 2019 EPS outlook benefit Fresenius Medical's (FMS) Q2 earnings. However, soft performance at Latin America remains a woe.

Zacks Equity Research

The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS

by Zacks Equity Research

The Zacks Analyst Blog Highlights: DaVita, Fresenius, Baxter, Amgen and CVS

Tirthankar Chakraborty headshot

Trump's Order on Kidney Care Lifts These Dialysis Stocks

by Tirthankar Chakraborty

Dialysis stocks move north after Trump signs an executive order designed to reform the nation's kidney treatment industry.

Mitchell Moore headshot

Trump's Kidney Disease Executive Order May Boost This Health Stock, Tank Others

by Mitchell Moore

President Trump signed an executive order Wednesday that will encourage an increase in kidney transplants. This transplant diagnostic company stands to grow significantly, while dialysis companies will take a hit.

Zacks Equity Research

Fresenius Set for Global Expansion of Research Activities

by Zacks Equity Research

Fresenius Medical Care (FMS) aims to expand the scope of its clinical research activities through an integration move.

Zacks Equity Research

Cara Shares Up on Positive Phase III Data for Itchiness Drug

by Zacks Equity Research

Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus.

Zacks Equity Research

Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

Fresenius Medical (FMS) gains from solid international revenues in Q1.

Zacks Equity Research

Fresenius Medical to Make Huge Investments, Competition Rife

by Zacks Equity Research

Fresenius Medical (FMS) is likely to make huge investments in India and China.

Zacks Equity Research

Fresenius Medical's New Hemodialysis Software Gets FDA Nod

by Zacks Equity Research

Fresenius Medical (FMS) offers a wide range of HD and PD dialysis products.